Group 1 - Han's Biopharma (3378.HK) listed on the Hong Kong Stock Exchange on December 23, raising a total of HKD 586 million by offering 18.32 million shares at HKD 32 per share, with a market capitalization of nearly HKD 4.4 billion [1] - Following the IPO, the stock price fell significantly, closing at HKD 17.2 per share, representing a decline of 46.25% and a total market value of HKD 2.343 billion [1] - The company, founded in 2014, focuses on developing innovative drugs for precise treatment of cancer and autoimmune diseases, with a pipeline of 10 candidate drugs, including 3 in clinical stages and 7 in preclinical stages [1] Group 2 - The core product, HX009, is a self-developed dual-function antibody fusion protein that has completed Phase I clinical trials in Australia and China, and is currently undergoing Phase Ib/I/IIa clinical trials for advanced melanoma, relapsed/refractory EBV-positive non-Hodgkin lymphoma, and advanced biliary cancer in China [1] - The company also has two other main clinical-stage products: HX301, a multi-target kinase inhibitor in Phase II trials for glioblastoma, and HX044, a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein in Phase I/IIa trials for advanced solid tumors [2] - The founder, Zhang Faming, is a professor and doctoral supervisor at Wuhan University, with a history of entrepreneurship in the innovative drug sector, having established multiple companies in the Wuhan East Lake High-tech Zone, which has a significant number of listed companies in the life and health sector [2]
湖北新增一家上市公司，翰思艾泰登陆港交所